www.uniqure.com/investors-media/press-releases
|
strategische Reorganisation
www.fiercebiotech.com/biotech/...p-gene-therapies-clinic-2027
MK 321 Mio. $ deutlich unter Cash.
Zahlen für Q3/23
Presented promising clinical update from U.S. and European Phase I/II trials of AMT-130 in Huntington’s disease; Up to three years of follow-up data to be presented in mid-2024; Regulatory interactions and clarity on potential strategies for clinical development expected in 2024
~ Announced FDA clearance of two Investigational New Drug (IND) applications; Initiation of Phase I/II clinical trials in mesial temporal lobe epilepsy (mTLE) and Fabry disease, in addition to SOD1-ALS, are expected in the first half of 2024
Announced strategic reorganization to advance multiple clinical-stage programs and deliver $180 million of cost savings over the next three years
www.uniqure.com/investors-media/press-releases
238 Mio. $ MK vs. 618 Mio. $ Cash (bis Q2/27)
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
4 | 109 | uniQure N.V. top oder flop!? | ktm85 | Balu4u | 15.03.24 22:12 |